BioCentury
ARTICLE | Clinical News

Boniva IV ibandronate regulatory update

July 23, 2012 7:00 AM UTC

Chugai submitted an NDA to the Japanese Ministry of Health, Labor and Welfare (MHLW) for monthly IV ibandronate for osteoporosis. Chugai partnered with Taisho in 2006 to co-develop and co-market the bisphosphonate that inhibits osteoclast-mediated bone resorption in Japan (see BioCentury, Sept. 18, 2006). The partners are developing a monthly oral formulation, which is in Phase II testing. Chugai is majority owned by Roche ...